Renaissance Capital logo

Orphazyme Priced, Nasdaq: ORPH

Danish late-stage biotech developing protein therapies for rare neurodegenerative diseases.

Industry: Health Care

Latest Trade: $4.09 -0.08 (-1.9%)

First Day Return: -11.7%

Return from IPO: -62.1%

Industry: Health Care

We are a late-stage biopharmaceutical company harnessing the amplification of Heat Shock Proteins, or HSPs, in order to develop and commercialize novel therapeutics for the treatment of neurodegenerative orphan diseases. In July 2020, we completed a rolling submission of a new drug application, or NDA, for our product candidate, arimoclomol, with the FDA for Niemann-Pick disease Type C, or NPC, and intend to submit a marketing authorization application, or MAA, to the European Medicines Agency, or EMA, in the second half of 2020. Arimoclomol is also in registrational clinical trials for the treatment of Amyotrophic Lateral Sclerosis, or ALS, and Sporadic Inclusion Body Myositis, or sIBM, and we intend to advance into pivotal-stage clinical development in neurological Gaucher disease. Arimoclomol is an orally- or naso/gastrically-administered small molecule that crosses the blood-brain barrier and is designed to selectively amplify the natural role of endogenous HSPs, which protect against cellular toxicity caused by protein misfolding, aggregation and lysosomal dysfunction. In our Phase 2/3 clinical trial of arimoclomol in NPC, we have observed evidence of slowing of disease progression, supporting our registration effort in the United States and Europe.
more less
IPO News for Orphazyme
more
IPO Data
IPO File Date 09/04/2020
Offer Price $11.00
Price Range $11.00 - $11.00
Offer Shares (mm) 7.6
Deal Size ($mm) $84
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 09/28/2020
Offer Price $11.00
Price Range $11.00 - $11.00
Offer Shares (mm) 7.6
Deal Size ($mm) $84
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Copenhagen, Denmark
Founded 2009
Employees 114
Website www.orphazyme.com